Page last updated: 2024-08-21

quinazolines and oxazoles

quinazolines has been researched along with oxazoles in 59 studies

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (10.17)	18.7374
1990's	3 (5.08)	18.2507
2000's	2 (3.39)	29.6817
2010's	6 (10.17)	24.3611
2020's	42 (71.19)	2.80

Authors

Authors	Studies
Diamantis, W; Ludwig, BJ; Sofia, RD	1
Ballard, F; Kucharczyk, N; Myers, G; Sofia, RD; Yang, J	1
Douglas, JF; Edelson, J; Ludwig, BJ	1
Banerjee, BN; Ivins, NJ; Ludwig, BJ; Sofia, RD	1
Diamantis, W; Edelson, J; Gordon, R; Ludwig, BJ; Sofia, RD	1
Ferber, RH; Parrish, SL; Vigdahl, RL	1
Nakahara, Y; Shimamine, M; Takahashi, K	1
Bollen, M; De Smedt, H; Himpens, B	1
Bekhit, AA; Farghaly, AM; Khalil, MA; Soliman, R	1
Cascioferro, S; Daidone, G; Maggio, B; Plescia, F; Raffa, D; Schillaci, D	1
Gdaniec, M; Kornicka, A; Saczewski, F	1
Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY	1
Imaizumi, S; Miura, S; Saku, K; Uehara, Y; Yahiro, E	1
Cao, PR; Huang, W; Kong, YL; Wu, QD; Xu, JH; Ye, M; Zhang, M; Zheng, W	1
Chen, DQ; Ding, J; Geng, MY; Liu, HC; Shen, AJ; Shen, JK; Sun, JY; Wang, X; Wang, YQ; Xiong, B; Zhang, MM; Zheng, M	1
Byrjalsen, I; Christiansen, C; Gardner, S; Goodman, Z; Henriksen, K; Karsdal, MA; Krag, A; Leeming, DJ; Nielsen, MJ; Patel, K; Schuppan, D	1
Hino, K; Horigome, K; Ikeya, M; Komura, S; Nagata, S; Nishio, M; Ohta, A; Okanishi, Y; Toguchida, J; Yamada, Y; Zhao, C	1
Abramson, V; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Braga, S; Cameron, D; Carey, LA; Curigliano, G; Duhoux, FP; Feng, W; Gelmon, K; Greil, R; Hamilton, E; Hortobagyi, G; Hurvitz, SA; Jakobsen, E; Krop, I; Lin, NU; Loi, S; Loibl, S; Müller, V; Murthy, RK; Okines, A; Oliveira, M; Palanca-Wessels, MC; Paplomata, E; Pegram, M; Shachar, SS; Slamon, D; Walker, L; Winer, EP	1
de Vries, P; Forero-Torres, A; Kulukian, A; Lee, P; Peterson, S; Rosler, R; Taylor, J; Watson, D	1
Printz, C	1
Barry, WT; Freedman, RA; Krop, I; Lawler, E; Leone, JP; Li, T; Lin, NU; Metzger Filho, O; Tan-Wasielewski, Z; Tolaney, SM; Trippa, L; Walker, L; Winer, EP; Younger, J	1
Abramson, V; An, X; Anders, C; Bachelot, T; Bedard, PL; Borges, V; Cameron, D; Carey, L; Chien, AJ; Conlin, A; Curigliano, G; DiGiovanna, MP; Gelmon, K; Hamilton, E; Hurvitz, S; Lin, NU; Loi, S; Loibl, S; Mayor, J; McGoldrick, S; Mueller, V; Murthy, RK; O'Regan, R; Okines, A; Oliveira, M; Paplomata, E; Wardley, A; Winer, EP; Zelnak, A	1
Benson, JR; Dumitru, D; Jatoi, I	1
Lee, A	1
Rugo, HS	1
Abdulrasool, LI; Alley, SC; Dailey, B; DeChenne, S; Endres, CJ; Lee, AJ; Mayor, JG; Rustia, EL; Topletz-Erickson, AR; Walker, LN; Wise, AL	1
Gelmon, KA; Tesch, ME	1
Amiri-Kordestani, L; Beaver, JA; Chen, W; Chen, XH; Cheng, J; Fan, J; Fiero, MH; Goldberg, KB; Gong, Y; Li, F; Pazdur, R; Pierce, WF; Ricks, TK; Shah, M; Song, P; Tang, S; Theoret, MR; Wedam, S; Xia, H; Yu, J; Zhang, X	1
Curigliano, G; Prat, A; Tarantino, P	1
Al-Zaqri, N; Alsalme, A; Pooventhiran, T; Rao, DJ; Rao, SS; Thomas, R	1
Crimini, E; Curigliano, G; Giugliano, F; Morganti, S; Tarantino, P; Uliano, J	1
Cardoso, F; Cortes, J; Curigliano, G; Prat, A; Tarantino, P	1
Munshi, A; Singla, H	1
Exman, P; Tolaney, SM	1
Boikos, SA; Dozmorov, MG; E Koblinski, J; Faber, AC; Fairchild, CK; Floros, KV; Hu, B; Jacob, S; Kurupi, R; Puchalapalli, M; Scaltriti, M	1
Chen, R; Jing, W; Li, W; Luo, J; Peng, S; Su, X; Wang, Z; Ye, X; Zhou, M	1
Corti, C; Criscitiello, C	1
Kreipe, HH; Sinn, P	1
Isaacs, C; O'Regan, R; O'Shaughnessy, JA	1
Borsellino, N; Galanti, D; Gori, S; Incorvaia, L; Inno, A; La Vecchia, M; Russo, A	1
Martínez-Sáez, O; Prat, A	1
Bishopric, NH; Dabas, N; Dempsey, N; Kropotova, Y; Lippman, M; Rosenthal, A	1
Hua, J; Sun, Y; Yuan, Y; Zhang, L; Zhang, Z	1
Aithal, S; Arkenau, HT; Block, M; Boyle, F; Brenner, A; Cameron, D; Cancel, M; Cold, S; Colleoni, M; Crouzet, L; Curigliano, G; Curtit, E; DeBusk, K; Fehrenbacher, L; Feng, W; Ferrario, C; Gelmon, K; Hahn, O; Hamilton, E; Harder Brix, E; Iqbal, N; Jakobsen, E; Mueller, V; Muñoz-Mateu, M; Paplomata, E; Poosarla, T; Ramos, J; Siadak, M; Stringer-Reasor, E; Wardley, A; Zelnak, A	1
Dong, L; Li, Y; Lin, S; Nian, D; Wang, R; Weng, X; Xu, X; Zhong, L; Zhou, W	1
Bartolini, S; Brandes, AA; Di Battista, M; Di Nunno, V; Franceschi, E; Gatto, L; Lodi, R; Maggio, I; Minichillo, S; Mura, A; Tosoni, A	1
Ballman, KV; Blinder, V; Borges, VF; Carey, LA; Goetz, MP; Irvin, WJ; Kommalapati, A; Krop, I; Lee, M; McCall, L; Mitchell, M; O'Sullivan, CC; Partridge, AH; Symmans, WF; Tung, NM; Weiss, A; Zemla, T	1
Arribas, J; Chandarlapaty, S; de Stanchina, E; Ferraro, E; Kulick, A; Lahuerta, EJA; Li, Q; Morales, CB; Razavi, P; Reis-Filho, J; Rosen, N; Ross, D; Safonov, A; Smith, AE; Solit, DB	1
Borges, V; Cameron, D; Carey, LA; Curigliano, G; Feng, W; Gelmon, K; Hamilton, E; Hortobagyi, GN; Hurvitz, S; Krop, I; Loi, S; Loibl, S; Mueller, V; Murthy, R; Okines, A; Paplomata, E; Pegram, M; Ramos, J; Slamon, D; Winer, E	1
Bachelot, T; Bailleux, C; Darlix, A; Jacot, W	1
Ahmed, AU; Balyasnikova, IV; Burga, R; Castro, B; Cordero, A; Fares, J; Kanojia, D; Lee-Chang, C; Lesniak, MS; Miska, J; Petrosyan, E; Ramsey, MD; Rashidi, A; Schwartz, CW; Xiao, T; Zhang, P	1
Ahn, D; Bekaii-Saab, T; Walden, D	1
Ennett, MD; Kaplan, HG; Kullnat, JA; Rinn, KJ; Scott, EL; Wu, AY; Yan, F	1
Ayala, R; Gong, KW; Huang, HKT; Issakhanian, S; Lu, M; Luo, T; Madrid, AM; McDermott, MSJ; O'Brien, NA; Slamon, DJ; Zhang, J	1
Alley, SC; Cardinal, KA; Chin, A; Endres, CJ; Henderson, C; Kumar, V; Lee, AJ; Neace, C; Regal, K; Sun, H; Topletz-Erickson, A; Vo, A; Wienkers, L	1
Sahu, RP; Sirhan, Z; Thyagarajan, A	1
Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L	1
Gong, Y; Hu, M; Li, J; Li, Y; Liu, C; Liu, Z; Xie, Y; Ying, B; Zhou, H	1

Reviews

13 review(s) available for quinazolines and oxazoles

Article	Year
Chymase inhibitors. Current pharmaceutical design, 2013, Volume: 19, Issue:17 Topics: Acetamides; Animals; Atrial Fibrillation; Azetidines; Benzoates; Cardiovascular Diseases; Chymases; Heart Failure; Humans; Hypertension; Mast Cells; Oxazoles; Pyrimidines; Quinazolines; Sulfonamides	2013
Tucatinib: First Approval. Drugs, 2020, Volume: 80, Issue:10 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Approval; Female; Humans; Molecular Structure; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2	2020
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. Drugs, 2020, Volume: 80, Issue:17 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2020
Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert opinion on biological therapy, 2021, Volume: 21, Issue:2 Topics: Antibodies, Monoclonal; Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab	2021
Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica et biophysica acta. Reviews on cancer, 2021, Volume: 1875, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Kaplan-Meier Estimate; Oxazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab	2021
HER2-positive metastatic breast cancer: a comprehensive review. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Female; Humans; Immunoconjugates; Neoplasm Metastasis; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab	2021
[Relevant mutations in predictive breast cancer pathology]. Der Pathologe, 2021, Volume: 42, Issue:4 Topics: Breast Neoplasms; Female; Humans; Mutation; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2	2021
Current treatment options for HER2-positive breast cancer patients with brain metastases. Critical reviews in oncology/hematology, 2021, Volume: 161 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Humans; Oxazoles; Pyridines; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab	2021
Current and Future Management of HER2-Positive Metastatic Breast Cancer. JCO oncology practice, 2021, Volume: 17, Issue:10 Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines	2021
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast cancer research and treatment, 2021, Volume: 188, Issue:1 Topics: Breast Neoplasms; Cardiotoxicity; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Risk Factors; Trastuzumab	2021
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? Clinical drug investigation, 2021, Volume: 41, Issue:9 Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2	2021
Bulletin du cancer, 2021, Volume: 108, Issue:11S Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Cranial Irradiation; Disease Progression; Female; Humans; Lapatinib; Life Expectancy; Magnetic Resonance Imaging; Metastasectomy; Middle Aged; Oxazoles; Pyridines; Quinazolines; Quinolines; Radiosurgery; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab	2021
The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer. Military Medical Research, 2022, 07-13, Volume: 9, Issue:1 Topics: Breast Neoplasms; Female; Humans; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; United States	2022

Trials

7 trial(s) available for quinazolines and oxazoles

Article	Year
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. American journal of physiology. Gastrointestinal and liver physiology, 2016, 12-01, Volume: 311, Issue:6 Topics: Biomarkers; Collagen Type III; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Oxazoles; Patient Selection; Quinazolines; Thiazolidinediones; Tyrosine	2016
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England journal of medicine, 2020, 02-13, Volume: 382, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Consolidation Chemotherapy; Diarrhea; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Oxazoles; Progression-Free Survival; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab	2020
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2020
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 08-10, Volume: 38, Issue:23 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease Progression; Double-Blind Method; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult	2020
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. Journal of clinical pharmacology, 2021, Volume: 61, Issue:4 Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Biological Transport; Creatinine; Cross-Over Studies; Dogs; Female; Glomerular Filtration Rate; Healthy Volunteers; HEK293 Cells; Humans; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Male; Metformin; Middle Aged; Organic Cation Transport Proteins; Organic Cation Transporter 2; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Young Adult	2021
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future oncology (London, England), 2021, Volume: 17, Issue:34 Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxazoles; Placebos; Prospective Studies; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2	2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Disease-Free Survival; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Trastuzumab	2022

Other Studies

39 other study(ies) available for quinazolines and oxazoles

Article	Year
Pharmacological properties of 2,3-dihydro-9H-isoxazolo [3,2-b] quinazolin-9-one (W-2429. Part 1: Analgesic, antipyretic and antiedema activity. Arzneimittel-Forschung, 1977, Volume: 27, Issue:4 Topics: Administration, Oral; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Aspirin; Body Temperature; Dextropropoxyphene; Drug Interactions; Drug Tolerance; Edema; Fever; Humans; Injections, Intravenous; Isoxazoles; Lethal Dose 50; Male; Mice; Narcotic Antagonists; Oxazoles; Quinazolines; Rats; Substance-Related Disorders; Time Factors	1977
The disposition of 3-methyl-2,3-dihydro-9H-isoxazolo[3,2-b]-quinazolin-9-one (W-2451). Archives internationales de pharmacodynamie et de therapie, 1979, Volume: 239, Issue:2 Topics: Analgesics; Animals; Biotransformation; Blood Proteins; Dogs; Haplorhini; Humans; In Vitro Techniques; Isoxazoles; Liver; Male; Oxazoles; Quinazolines; Rats; Species Specificity; Time Factors; Tissue Distribution	1979
Absorption, distribution and metabolic fate of 2,3-dihydro-9H-isoxazolo-[3,2-b]quinazolin-9-one (W2429). Arzneimittel-Forschung, 1977, Volume: 27, Issue:4 Topics: Administration, Oral; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Blood Proteins; Dogs; Humans; Intestinal Absorption; Isoxazoles; Kinetics; Male; Mice; Oxazoles; Protein Binding; Quinazolines; Rats	1977
Toxicological investigation of 2,3-dihydro-9H-isoxazolo[3,2-b]quinazolin-9-one (W-2429). Acute and subacute toxicity in mice, rats and dogs. Arzneimittel-Forschung, 1977, Volume: 27, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Cell Count; Blood Chemical Analysis; Body Weight; Dogs; Female; Isoxazoles; Lethal Dose 50; Male; Mice; Organ Size; Oxazoles; Quinazolines; Rats; Spermatogenesis; Time Factors	1977
Pharmacological properties of 2,3-dihydro-9H-isoxazolo[3,2-b]-quinazolin-9-one (W-2429. Part 2: General pharmacological investigation. Arzneimittel-Forschung, 1977, Volume: 27, Issue:4 Topics: Anesthetics, Local; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Antitussive Agents; Cats; Diuresis; Dogs; Enzyme Induction; Female; Gastrointestinal Hemorrhage; Gastrointestinal Motility; Guinea Pigs; Hemodynamics; Isoxazoles; Male; Mice; Motor Activity; Muscle Contraction; Muscle, Smooth; Oxazoles; Postural Balance; Prostaglandin-Endoperoxide Synthases; Quinazolines; Rabbits; Rats; Respiration; Sleep; Stomach Ulcer; Time Factors	1977
Comparison of sulfinpyrazone and BL-3459 with S - 20344, a potent new antithrombotic agent. Thrombosis research, 1981, Mar-15, Volume: 21, Issue:6 Topics: Animals; Fibrinolytic Agents; Humans; Imidazoles; Male; Oxazoles; Platelet Aggregation; Prostaglandins E; Quinazolines; Rats; Sulfinpyrazone; Thrombosis	1981
[Studies on the identification of psychotropic substances. IX. Preparation and various analytical data of reference standard of new psychotropic substances, N-ethyl methylenedioxyamphetamine, N-hydroxy methylenedioxyamphetamine, mecloqualone, 4-methylamin Eisei Shikenjo hokoku. Bulletin of National Institute of Hygienic Sciences, 1993, Issue:111 Topics: 3,4-Methylenedioxyamphetamine; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Gas Chromatography-Mass Spectrometry; Morpholines; Oxazoles; Phenmetrazine; Psychotropic Drugs; Quinazolines; Spectrophotometry	1993
Modulation of nucleocytosolic [Ca2+] gradient in smooth muscle by protein phosphorylation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 1994, Volume: 8, Issue:11 Topics: Adenosine Triphosphate; Animals; Benzoquinones; Calcium; Cell Line; Cell Nucleus; Colforsin; Cricetinae; Cytosol; Diacylglycerol Kinase; Epidermal Growth Factor; Ethers, Cyclic; Homeostasis; Kinetics; Lactams, Macrocyclic; Leiomyosarcoma; Marine Toxins; Mesocricetus; Models, Biological; Muscle, Smooth; Okadaic Acid; Oxazoles; Phosphoproteins; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Piperidines; Protein Kinase C; Protein Kinases; Protein Tyrosine Phosphatases; Quinazolines; Quinazolinones; Quinones; Rifabutin; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured	1994
Non-steroidal anti-inflammatory agents: novel pyrazolyl-, 1,2-oxazolyl-, and 1,3-diazinyl derivatives of 4(3H)-quinazolinones. Archiv der Pharmazie, 1994, Volume: 327, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Granuloma; Male; Oxazoles; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley	1994
Synthesis and antileukemic activity of new 3-(5-methylisoxazol-3-yl) and 3-(pyrimidin-2-yl)-2-styrylquinazolin-4(3H)-ones. Farmaco (Societa chimica italiana : 1989), 2004, Volume: 59, Issue:6 Topics: Animals; Antineoplastic Agents; Colchicine; Czech Republic; Drug Evaluation, Preclinical; HL-60 Cells; Humans; K562 Cells; Leukemia L1210; Molecular Structure; Oxazoles; Quinazolines	2004
Synthesis, molecular structure and reactivity of 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines. Molecules (Basel, Switzerland), 2004, Feb-28, Volume: 9, Issue:3 Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Imidazoles; Oxazoles; Quinazolines	2004
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases. Journal of medicinal chemistry, 2012, Mar-22, Volume: 55, Issue:6 Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship	2012
Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Immunoenzyme Techniques; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2015
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells. Acta pharmacologica Sinica, 2016, Volume: 37, Issue:12 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterografts; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Oxazoles; Quinazolines; Resorcinols	2016
An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva. Stem cell reports, 2018, 11-13, Volume: 11, Issue:5 Topics: Activin Receptors, Type I; Animals; Benzodioxoles; High-Throughput Screening Assays; Humans; Induced Pluripotent Stem Cells; Mice, SCID; Mice, Transgenic; Myositis Ossificans; Ossification, Heterotopic; Oxazoles; Pyrimidines; Quinazolines; Reproducibility of Results; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Urea	2018
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. Molecular cancer therapeutics, 2020, Volume: 19, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Evaluation, Preclinical; Female; Humans; Mice; Mice, Nude; Neoplasms; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020
Addition of tucatinib to trastuzumab and chemotherapy improves survival for patients with metastatic, HER2-positive breast cancer. Cancer, 2020, 05-15, Volume: 126, Issue:10 Topics: Breast Neoplasms; Humans; Oxazoles; Pyridines; Quinazolines; Trastuzumab	2020
Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity. Future oncology (London, England), 2020, Volume: 16, Issue:21 Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemoprevention; Chemotherapy, Adjuvant; Female; Humans; Immune Checkpoint Inhibitors; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab	2020
Highlights from the 2019 San Antonio Breast Cancer Symposium. Clinical advances in hematology & oncology : H&O, 2020, Volume: 18, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Female; Humans; Immunoconjugates; Oxazoles; Paclitaxel; Prognosis; Pyridines; Quinazolines; Texas; Trastuzumab	2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 03-01, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Approval; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; United States; United States Food and Drug Administration	2021
New anti-HER2 agents for brain metastasis: histology-agnostic weapons? Breast cancer research and treatment, 2021, Volume: 185, Issue:3 Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab	2021
Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity. Journal of molecular modeling, 2020, Nov-16, Volume: 26, Issue:12 Topics: Antineoplastic Agents; Antiviral Agents; Betacoronavirus; Binding Sites; Coronavirus 3C Proteases; Cysteine Endopeptidases; Drug Repositioning; Electrons; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxazoles; Protease Inhibitors; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; Pyridines; Quantum Theory; Quinazolines; SARS-CoV-2; Thermodynamics; Viral Nonstructural Proteins	2020
HER2 Tyrosine Kinase Inhibitors in the Sensitization to Cancers Resistant to HER2 Antibodies. Critical reviews in oncogenesis, 2020, Volume: 25, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Breast Neoplasms; Female; Humans; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab	2020
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Cell death & disease, 2021, 02-15, Volume: 12, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclic N-Oxides; Drug Synergism; Female; Gene Amplification; Humans; Indoles; Indolizines; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oxazoles; Protein Kinase Inhibitors; Pyridines; Pyridinium Compounds; Quinazolines; Quinolines; Random Allocation; Receptor, ErbB-2; Sulfonamides; Xenograft Model Antitumor Assays	2021
In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells. Oncology reports, 2021, Volume: 45, Issue:3 Topics: Adenosine Triphosphatases; Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzimidazoles; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Male; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Oxazoles; Pyridines; Quinazolines; Side-Population Cells; Tumor Cells, Cultured	2021
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. ESMO open, 2021, Volume: 6, Issue:2 Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2	2021
Neratinib: an option for HER2-positive metastatic breast cancer. Clinical advances in hematology & oncology : H&O, 2020, Volume: 18 Suppl 15, Issue:9 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Disease Management; Female; Fulvestrant; Humans; Neoplasm Metastasis; Oxazoles; Pyridines; Quality of Life; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2020
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells. Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Iridoids; Neoadjuvant Therapy; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Uncoupling Protein 2	2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). European journal of cancer (Oxford, England : 1990), 2021, Volume: 153 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Middle Aged; Oxazoles; Pyridines; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Young Adult	2021
Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis. Clinical breast cancer, 2022, Volume: 22, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Neoplasm Staging; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Treatment Outcome; United States	2022
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature communications, 2021, 11-18, Volume: 12, Issue:1 Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; MAP Kinase Signaling System; Mutation; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Tumor Escape	2021
Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 01-04, Volume: 119, Issue:1 Topics: Animals; Antineoplastic Agents, Immunological; Brain Neoplasms; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms, Experimental; Neural Stem Cells; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2022
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. Expert opinion on investigational drugs, 2022, Volume: 31, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Lung Neoplasms; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab	2022
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report. Journal of the National Comprehensive Cancer Network : JNCCN, 2022, 04-11, Volume: 20, Issue:7 Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab	2022
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies. Molecular cancer therapeutics, 2022, 05-04, Volume: 21, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Oxazoles; Phosphatidylinositol 3-Kinases; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab	2022
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Humans; Microsomes, Liver; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Stereoisomerism	2022
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers. Clinical pharmacokinetics, 2022, Volume: 61, Issue:10 Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide	2022
Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. European journal of medicinal chemistry, 2022, Dec-15, Volume: 244 Topics: Breast Neoplasms; Female; Humans; Oxazoles; Pyridines; Quinazolines; Receptor, ErbB-2	2022
In brief: A second indication for tucatinib (Tukysa). The Medical letter on drugs and therapeutics, 2023, 02-20, Volume: 65, Issue:1670 Topics: Humans; Oxazoles; Pyridines; Quinazolines	2023